-
Montana and Wyoming have enacted opioid prescribing limits focused on “opioid-naïve” patients. See our blog to learn the parameters and exceptions to the legislation and impact on workers’ compensation.
-
Teva Pharmaceuticals has launched an authorized generic version of Flector Patch 1.3% (diclofenac epolamine topical patch), originally manufactured by Pfizer, in the United States (U.S.). Additionally, Greenstone, a Pfizer Company, is also launching an authorized generic version of Flector Patch.
-
The newly-elected Governor of Florida has paved the way for Florida residents in the medical marijuana program to smoke the product. This new option is available following the governor signing Senate Bill 182 into law on March 18, 2019.
-
Oklahoma has enacted a law that adds rules and provides structure for the medical marijuana initiative that voters approved in 2018.
-
Whether medical marijuana will be permitted in workers’ compensation is a hot topic. A recent Supreme Court decision in New Hampshire may open the door for medical marijuana in workers’ comp. Read more on our Policy Matters blog.
-
Increasingly, PBMs are relying on massive stores of data to identify broader patterns that inform individual prescription decisions. According to David Young, President and CEO of Optum Workers’ Compensation and Auto No-fault, this is a PBM’s true value proposition.
-
Treatment-resistant depression (TRD), is typically defined as failing trials of at least two antidepressant treatments for major depressive disorder. The FDA is expected to make its decision in early March. See potential impact for workers’ comp on our blog.